Clinical Trials Logo

Clinical Trial Summary

Mindsets are lenses or frames of mind that orient individuals to a particular set of expectations and associations. This study aims to leverage specific and empirically supported mindsets (i.e., 'cancer is manageable' and 'the body is capable') to reduce distress and improve physical health and psychological wellbeing in patients with cancer being treated with curative intent. This intervention will take the form of several brief documentary style film segments which feature both cancer survivors and experts in the fields of Oncology, Psychology, and Psychiatry.

Although no mindset-targeted interventions have been studied in cancer patients to date, other psychosocial interventions have demonstrated efficacy in treating emotional distress and improving quality of life in this population. However, compared with these standard interventions, mindset interventions need not be lengthy, complex, or costly to yield major effects. Thus, this project aims to lay the groundwork for future scalable and efficient interventions that can meaningfully reduce distress and improve health and wellbeing in this population.


Clinical Trial Description

A diagnosis of cancer causes significant emotional distress in a substantial proportion of patients. This distress impacts physical and mental health outcomes and often goes unrecognized and untreated. Psychosocial interventions have been proven effective in ameliorating cancer related distress. While the literature supports the use of standard psychosocial interventions like Mindfulness Based Stress Reduction (MBSR) and Cognitive Behavioral Therapy (CBT) for cancer patients, effects are typically only found in interventions lasting longer than 12 weeks. This constraint represents a considerable time commitment on the part of the patient and large financial commitment on the part of the healthcare system. As such, there is a need for brief, scalable, cost-effective interventions that are informed by psychological theory but do not require access to trained mental health professionals and could potentially be delivered by oncology clinicians during cancer treatment without specialized referrals. This may also facilitate better comprehensive care for patients without insurance covering mental health services.

Interventions that target mindsets may be well suited to fill this need. A mindset is a lens or frame of mind that orients an individual to a particular set of associations and expectations. Mindsets may serve as an important psychosocial variable that can be leveraged to improve health outcomes. The impact of mindsets has been documented extensively in the context of stress, diet, and exercise. Mindsets also likely play a large role in shaping other clinical outcomes including blood pressure and hormone response as well. Because mindset interventions target specific mindsets rather than more general cognitive or affective processes, they can effectively shape downstream targets like attention, motivation, affect, and physiology despite their apparent brevity.

Mindsets in clinical populations have been relatively understudied. However, preliminary findings indicate that mindsets about the body, illness, and medications are significantly related to critical health outcomes and quality of life in individuals with chronic illness. For instance, patients with cancer who endorsed the mindset that cancer is a catastrophe reported lower levels of physical and social functioning, worse quality of life, and poorer perceived health. Conversely, patients who adopted the mindset that cancer is manageable or the mindset that cancer can be an opportunity to make important life changes or pursue goals reported better physical functioning, social functioning, perceived health, and quality of life.

This study aims to understand patient mindsets and quantify the impact of a highly targeted mindset intervention in a diverse population of patients with cancer. The investigators hypothesize that mindsets will also impact treatment efficacy, reporting and management of adverse events, physiological markers of health and disease, global functioning, quality of life, and fear of recurrence in individuals diagnosed with cancer and treated with curative intent. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03910283
Study type Interventional
Source Stanford University
Contact Sean R Zion, MA
Phone (585) 298-3887
Email szion@stanford.edu
Status Not yet recruiting
Phase N/A
Start date May 1, 2019
Completion date December 31, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT03977623 - Genomic Evaluation in Patients With Diffuse Large B Cell Lymphoma After First Relapse/Progression
Recruiting NCT02428751 - R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma Phase 3
Completed NCT02555267 - Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma
Active, not recruiting NCT02364050 - Prospective Data Collection of Elderly Patients With DLBCL Receiving at the Time of Diagnosis VGM
Terminated NCT00529503 - A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL Phase 2
Terminated NCT02413489 - An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma Phase 2
Completed NCT02086604 - Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma Phase 1
Completed NCT01421524 - Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma Phase 1
Recruiting NCT03600363 - A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma Patients Phase 2
Recruiting NCT03646422 - AEDV Registry of Primary Cutaneous Lymphoma
Recruiting NCT04446962 - LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV) Phase 1/Phase 2
Withdrawn NCT03241017 - Durvalumab in DLBCL After Autologous Transplant Phase 2
Recruiting NCT02928861 - 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Diffuse Large B-cell Lymphoma N/A
Recruiting NCT02931201 - Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Diffuse Large B-cell Lymphoma N/A
Terminated NCT02592876 - Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma Phase 2
Completed NCT00849147 - Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) Phase 2
Completed NCT00822432 - Coproporphyrine Isomers and Methotrexate Elimination N/A
Completed NCT03682796 - Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma Phase 1
Recruiting NCT04982471 - Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study
Completed NCT03744676 - A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) Phase 2